ZYPADHERA olanzapine 405mg powder and solvent for prolonged release suspension for injection (Germany)
Section 19A approved medicine
ZYPADHERA olanzapine 405mg powder and solvent for prolonged release suspension for injection (Germany)
Section 19A approval holder
Aborns Pharmaceuticals ABN 80 625 808 193
Phone
1300 117 772
Approved until
Status
Current
Medicines in short supply/unavailable
ZYPREXA RELPREVV olanzapine (as pamoate monohydrate) 405mg powder for injection vial with diluent vial - ARTG 143636
Indication(s)
ZYPADHERA is a long-acting injectable formulation of olanzapine indicated for maintenance treatment of schizophrenia in adult patients sufficiently stabilised during acute treatment with oral olanzapine. The effectiveness of ZYPADHERA is consistent with the established effectiveness of orally administered olanzapine for acute or maintenance treatment of schizophrenia.
Images
